ß-L-2 DEOXY NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Abstract

This invention is directed to a use of an effective amount of an anti-HBV biologically active 2-deoxy-ß-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2-deoxy-ß-L-erythro- pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight-chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, [illegible] derivative; and BASE is a purine or pyrimidine base which may be optionally substituted in the manufacture of a medicament for treating a host infected with hepatitis B. The 2-deoxy-ß-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2-deoxy-ß-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B-agent.

Figure 2



162162



G00002